Alfredo Soler Carracedo, RN, MSc, MSN, is a Research Nurse, Chelsea and Westminster Hospital, London, United Kingdom. Vitor Oliveira, PhD, is an Acting Instructor, School of Nursing, Department of Child, Family, and Population Health Nursing, University of Washington, Seattle, Washington, USA. Jorge Saz is a General Coordinator, Barcelona Checkpoint, Barcelona, Spain. Ferran Pujol is a Founder-Director, Barcelona Checkpoint, Barcelona, Spain. Ana Milinkovic, MD, PhD, MSc, is a Clinical Trials Physician, Chelsea and Westminster Hospital, London, United Kingdom. Allison Webel, RN, PhD, FAAN, is an Associate Dean for Research, School of Nursing, Department of Child, Family, and Population Health Nursing, University of Washington, Seattle, Washington, USA.
J Assoc Nurses AIDS Care. 2022;33(6):638-645. doi: 10.1097/JNC.0000000000000343. Epub 2022 Jun 7.
Adherence to antiretroviral therapy (ART) underpins the successful treatment of HIV infection. New long-acting injectable ART agents have recently been approved by the United States Food and Drug Administration, the European Medicines Agency, and Health Canada, among other regulatory agencies, but are not routinely given to people with HIV (PWH). In this cross-sectional survey study, PWH in the USA and Spain completed a survey exploring their preference regarding oral versus injectable ART. Chi-square tests were used to determine differences between variables and univariate and multivariate testing were used to examine factors associated with preference. The most preferred ART option in the USA was one ART tablet once a day (44.4%), whereas in Spain it was an intramuscular (IM) ART injection once every two months (61.9%). Among all participants, having received an HIV diagnosis more recently, less satisfaction with current ART, and having received an IM injection in the past were associated with a preference for IM ART. Limitations include the cross-sectional design and the convenient sample. Further research employing mixed methodology is warranted.
抗逆转录病毒疗法（ART）的依从性是成功治疗 HIV 感染的基础。新的长效注射型 ART 药物最近已获得美国食品和药物管理局、欧洲药品管理局和加拿大卫生部等监管机构的批准，但尚未常规用于 HIV 感染者（PWH）。在这项横断面调查研究中，美国和西班牙的 PWH 完成了一项调查，探讨他们对口服和注射型 ART 的偏好。卡方检验用于确定变量之间的差异，单变量和多变量检验用于检查与偏好相关的因素。在美国，最受欢迎的 ART 选择是每天服用一片 ART（44.4%），而在西班牙，最受欢迎的选择是每两个月肌内注射一次 ART（61.9%）。在所有参与者中，最近被诊断出 HIV、对当前 ART 治疗的满意度较低以及过去接受过肌内注射的人更倾向于接受肌内注射 ART。研究的局限性包括横断面设计和方便样本。需要采用混合方法进一步研究。
